J-147 vs NSI-189

J-147 wins for: broad neuroprotection via mitochondrial modulation, strong data in neurotoxicity and mild cognitive impairment models, once-daily convenience, and stacking synergies in longevity-focused research protocols.

NSI-189 wins for: hippocampal neurogenesis, documented persistence of effects post-cycle, and targeted reversal of anhedonia or post-SSRI cognitive flattening. Its selective mechanism avoids monoaminergic side effects, and the long half-life supports flexible dosing schedules.

Pick J-147 if:

• The research protocol targets mitochondrial dysfunction, aging, or neuroinflammation.
• The use case is recovery from neurotoxicity (e.g., stimulant or alcohol insult).
• The interest is in stacking with rapamycin, fisetin, or broad-spectrum longevity compounds.
• Neuroprotection is prioritized over acute mood or memory boosts.
• Once-daily with-fats administration is preferred for protocol simplicity.

Pick NSI-189 if:

• The focus is hippocampal neurogenesis and durable mood or memory improvements.
• The goal is support for anhedonia, post-SSRI/post-trauma cognitive rebuilding, or depression-adjacent scenarios in research.
• Research cycles aim for measurable effects that persist after the protocol (off-cycle carryover).
• Monoaminergic side effects are a deal-breaker — NSI-189 avoids them.
• A longer half-life and pulsed dosing fits the research schedule better than daily administration.